Security
MeiraGTx Holdings plc Ordinary Shares · MGTX
MGTXNASDAQCommon stockCurrentCIK 1735438Updated Nov 13, 2026
MGTX price & chart
Loading TradingView…
NASDAQ:MGTX on TradingView ↗About the company
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, radiation-induced xerostomia, and Parkinson’s disease. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two
In the news
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Seeking Alpha
MeiraGTx: The Data Held Up, The Valuation Didn't (Rating Downgrade) ↗
GLP-1 obesity drugs: A market that's getting more crowded ↗
Biotech Breakout: What's in focus after Moderna's cancer win? ↗
SEC disclosures
MeiraGTx Holdings plc files 8-K: Material Event ↗
Recent filings
S-3ASR filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 189,471,000Source | 299,488,000Source | 396,449,000Source | 198,716,000Source | 266,651,000Source | 244,655,000Source | 224,014,000Source | 309,235,000Source | 244,430,000Source | 269,751,000Source | 326,744,000Source | 318,237,000Source |
| Property, Plant and Equipment, NetUSD | 107,653,000Source | 112,541,000Source | 100,333,000Source | 110,816,000Source | 108,844,000Source | 102,573,000Source | 104,408,000Source | 111,412,000Source | 105,465,000Source | 102,878,000Source | 115,896,000Source | 109,266,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 653,000Source | 951,000Source | 421,000Source | 742,000Source | 969,000Source | 494,000Source | 773,000Source | 1,038,000Source | 578,000Source | 821,000Source | 1,118,000Source | 1,335,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,841,000Source | 122,873,000Source | 143,166,000Source | 32,166,000Source | 99,974,000Source | 71,541,000Source | 66,523,000Source | 119,206,000Source | 65,931,000Source | 103,659,000Source | 129,566,000Source | 115,516,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,808,000Source | 3,279,000Source | — | 2,319,000Source | 1,628,000Source | 3,263,000Source | 734,000Source | 10,915,000Source | 3,000,000Source | 707,000Source | 10,138,000Source | 21,334,000Source |
| Inventory, NetUSD | — | — | — | 314,000Source | — | — | 607,000Source | — | — | 385,000Source | — | — |
| Assets, CurrentUSD | 34,174,000Source | 139,046,000Source | 218,347,000Source | 47,084,000Source | 110,774,000Source | 96,201,000Source | 79,889,000Source | 149,300,000Source | 91,761,000Source | 123,518,000Source | 159,622,000Source | 154,339,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,064,000Source | 12,782,000Source | 11,524,000Source | 5,820,000Source | 13,823,000Source | 12,124,000Source | 6,348,000Source | 14,835,000Source | 12,852,000Source | 10,576,000Source | 15,910,000Source | 20,109,000Source |
| Other Assets, NoncurrentUSD | 1,111,000Source | 1,139,000Source | 1,362,000Source | 1,093,000Source | 1,139,000Source | 1,466,000Source | 1,032,000Source | 1,138,000Source | 1,147,000Source | 1,002,000Source | 1,917,000Source | 1,402,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 230,028,000Source | 203,752,000Source | 180,668,000Source | 195,756,000Source | 186,612,000Source | 302,785,000Source | 190,915,000Source | 187,501,000Source | 250,223,000Source | 201,924,000Source | 188,567,000Source | 200,499,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 2,000Source | 3,000Source | 3,000Source | 2,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 797,063,000Source | 763,204,000Source | 932,323,000Source | 791,280,000Source | 706,943,000Source | 820,018,000Source | 780,165,000Source | 699,531,000Source | 808,021,000Source | 773,565,000Source | 693,841,000Source | 581,893,000Source |
| Retained Earnings (Accumulated Deficit)USD | -831,311,000Source | -662,623,000Source | -701,816,000Source | -780,798,000Source | -623,293,000Source | -862,536,000Source | -742,003,000Source | -574,673,000Source | -816,223,000Source | -702,022,000Source | -554,231,000Source | -470,204,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,312,000Source | -4,848,000Source | 3,255,000Source | -7,525,000Source | -3,614,000Source | 2,578,000Source | -5,066,000Source | -3,126,000Source | 2,406,000Source | -3,719,000Source | -1,435,000Source | 6,047,000Source |
| Stockholders' Equity Attributable to ParentUSD | -40,557,000Source | 95,736,000Source | — | 2,960,000Source | 80,039,000Source | -58,130,000Source | 33,099,000Source | 121,734,000Source | -5,793,000Source | 67,827,000Source | 138,177,000Source | 117,738,000Source |
| Liabilities and EquityUSD | 189,471,000Source | 299,488,000Source | 396,449,000Source | 198,716,000Source | 266,651,000Source | 244,655,000Source | 224,014,000Source | 309,235,000Source | 244,430,000Source | 269,751,000Source | 326,744,000Source | 318,237,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 152,922,000Source | 59,418,000Source | 58,096,000Source | 53,436,000Source | 47,006,000Source | 176,127,000Source | 52,372,000Source | 47,543,000Source | 122,555,000Source | 60,783,000Source | 67,078,000Source | 82,072,000Source |
| Operating Lease, Liability, CurrentUSD | 2,475,000Source | 4,183,000Source | 2,260,000Source | 2,647,000Source | 4,212,000Source | 2,221,000Source | 3,297,000Source | 4,188,000Source | 2,851,000Source | 4,053,000Source | 4,193,000Source | 3,884,000Source |
| Accounts Payable, CurrentUSD | 21,537,000Source | 29,504,000Source | 11,668,000Source | 25,586,000Source | 21,398,000Source | 16,658,000Source | 20,290,000Source | 21,223,000Source | 10,066,000Source | 23,586,000Source | 16,042,000Source | 16,616,000Source |
| Operating Lease, Liability, NoncurrentUSD | 11,531,000Source | 9,610,000Source | 9,936,000Source | 4,049,000Source | 10,688,000Source | 10,611,000Source | 4,086,000Source | 11,796,000Source | 11,351,000Source | 7,523,000Source | 12,952,000Source | 17,331,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 186,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 23,872,000Source | 19,341,000Source | 21,225,000Source | 15,483,000Source | 16,928,000Source | 25,239,000Source | 23,964,000Source | 17,353,000Source | 32,893,000Source | 27,414,000Source | 42,639,000Source | 39,818,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 186,000Source |
| Stockholders' Equity Attributable to Noncontrolling Interest | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | 160,669,000Source | -38,795,000Source | -46,313,000Source | -39,981,000Source | -114,201,000Source | -147,791,000Source | -84,027,000Source | -129,615,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 3,155,000Source | 3,259,000Source | — | — | 3,008,000Source | 3,081,000Source | 12,542,000Source | 12,828,000Source | 13,730,000Source | 8,723,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 5,952,000Source | 6,304,000Source | — | — | 3,654,000Source | 4,887,000Source | 22,105,000Source | 25,191,000Source | 27,716,000Source | 28,623,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 7,909,000Source | -3,061,000Source | -12,313,000Source | 10,738,000Source | 2,330,000Source | 3,737,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -21,292,000Source | -24,038,000Source | -9,661,000Source | -25,955,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 17,810,000Source | -36,828,000Source | -46,359,000Source | -104,495,000Source | -105,365,000Source | -73,098,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -2,258,000Source | -1,710,000Source | -4,107,000Source | 23,479,000Source | 34,034,000Source | -44,963,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,008,000Source | 1,710,000Source | 3,826,000Source | 4,955,000Source | 20,174,000Source | 44,963,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 5,960,000Source | 2,761,000Source | 2,991,000Source | 2,340,000Source | 1,519,000Source | 2,774,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -10,113,000Source | 1,713,000Source | 12,272,000Source | 54,534,000Source | 84,023,000Source | 95,200,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 17,106,000Source | 125,029,000Source | 145,366,000Source | 34,424,000Source | 73,758,000Source | 68,610,000Source | 68,193,000Source | 105,668,000Source | 130,649,000Source | 115,516,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,710,000Source | 2,863,000Source | 11,036,000Source | 12,029,000Source | 13,054,000Source | 329,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 126,000Source | -233,000Source | 719,000Source | 1,501,000Source | 2,441,000Source | 674,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,952,000Source | 6,304,000Source | 3,779,000Source | 5,664,000Source | 3,654,000Source | 4,887,000Source | 22,105,000Source | 25,191,000Source | 27,716,000Source | 28,623,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | — | — | — | — | — | — | 36,000Source | 63,000Source | 153,000Source | 209,000Source | 177,000Source | 168,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 11,100,000Source | 11,400,000Source | 12,300,000Source | 7,300,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | -17,000Source | -6,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -1,558,000Source | 3,463,000Source | -1,466,000Source | 8,624,000Source | -2,837,000Source | 3,687,000Source | 2,146,000Source | -2,886,000Source | 9,300,000Source | -9,452,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -55,000Source | 122,000Source | -355,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | 1,365,000Source | 1,465,000Source | 172,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 13,616,000Source | 12,723,000Source | 12,013,000Source | 12,313,000Source | 8,928,000Source | 9,364,000Source | 52,897,000Source | 54,216,000Source | 47,293,000Source | 46,550,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 2,362,000Source | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Investment Income, InterestUSD | — | — | 161,000Source | 1,189,000Source | 706,000Source | 408,000Source | 189,000Source | 971,000Source | 1,818,000Source | 4,145,000Source | 2,272,000Source | 777,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -50,513,000Source | -39,330,000Source | 160,720,000Source | -38,795,000Source | -46,313,000Source | -39,981,000Source | -114,201,000Source | -147,791,000Source | -84,027,000Source | -129,615,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -50,513,000Source | -39,330,000Source | 160,720,000Source | -38,795,000Source | -46,313,000Source | -39,981,000Source | -114,201,000Source | -147,791,000Source | -84,027,000Source | -129,615,000Source |
| Operating ExpensesUSD | — | — | 46,461,000Source | 50,951,000Source | 77,009,000Source | 48,484,000Source | 41,110,000Source | 43,522,000Source | 187,359,000Source | 197,491,000Source | 151,078,000Source | 132,275,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,300,000Source | 1,400,000Source | 800,000Source | 1,300,000Source | 1,200,000Source | 1,300,000Source | 4,800,000Source | 5,600,000Source | 5,500,000Source | 5,300,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 6,418,000Source | 2,257,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 14,027,000Source | 4,482,000Source | 15,074,000Source | 59,390,000Source | 91,950,000Source | 25,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 62,000Source | 4,000Source | 257,000Source | — | 10,000Source | 231,000Source |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Income (Loss) from Equity Method Investments | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Unrealized Gain (Loss) on Derivatives | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 410,000Source | 10,910,000Source | 321,434,000Source | 3,691,000Source | 293,000Source | 1,926,000Source | 81,391,000Source | 33,279,000Source | — | — |
| Operating Income (Loss)USD | — | — | -46,051,000Source | -40,041,000Source | 244,425,000Source | -44,793,000Source | -40,817,000Source | -41,596,000Source | -105,968,000Source | -164,212,000Source | -137,061,000Source | -116,355,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -114,201,000Source | -147,791,000Source | -84,027,000Source | -129,615,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 2,362,000Source | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -50,513,000Source | -39,330,000Source | 160,720,000Source | -38,795,000Source | -46,313,000Source | -39,981,000Source | -114,201,000Source | -147,791,000Source | -84,027,000Source | -129,615,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.62Source | -0.55Source | 1.76Source | -0.48Source | -0.57Source | -0.51Source | -1.42Source | -2.12Source | -1.49Source | -2.87Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.62Source | -0.55Source | 1.71Source | -0.48Source | -0.57Source | -0.51Source | -1.42Source | -2.12Source | -1.49Source | -2.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 80,947,703Source | 71,633,150Source | 91,418,527Source | 80,585,625Source | 81,300,944Source | 79,032,341Source | 80,430,186Source | 69,822,353Source | 56,486,525Source | 45,177,857Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 80,947,703Source | 71,633,150Source | 93,805,296Source | 80,585,625Source | 81,300,944Source | 79,032,341Source | 80,430,186Source | 69,822,353Source | 56,486,525Source | 45,177,857Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 11,100,000Source | 11,400,000Source | 12,300,000Source | 7,300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -1,558,000Source | 3,463,000Source | -1,466,000Source | 8,624,000Source | -2,837,000Source | 3,687,000Source | 2,146,000Source | -2,886,000Source | 9,300,000Source | -9,452,000Source |
| General and Administrative ExpenseUSD | — | — | 13,616,000Source | 12,723,000Source | 12,013,000Source | 12,313,000Source | 8,928,000Source | 9,364,000Source | 52,897,000Source | 54,216,000Source | 47,293,000Source | 46,550,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -16,284,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 3,065,000Source | 3,357,000Source | 3,509,000Source | 3,034,000Source | 2,848,000Source | 3,043,000Source | 12,197,000Source | 13,272,000Source | 13,245,000Source | 4,946,000Source |
| Investment Income, InterestUSD | — | — | 161,000Source | 1,189,000Source | 706,000Source | 408,000Source | 189,000Source | 971,000Source | 1,818,000Source | 4,145,000Source | 2,272,000Source | 777,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -50,513,000Source | -39,330,000Source | 160,720,000Source | -38,795,000Source | -46,313,000Source | -39,981,000Source | -114,201,000Source | -147,791,000Source | -84,027,000Source | -129,615,000Source |
| Operating ExpensesUSD | — | — | 46,461,000Source | 50,951,000Source | 77,009,000Source | 48,484,000Source | 41,110,000Source | 43,522,000Source | 187,359,000Source | 197,491,000Source | 151,078,000Source | 132,275,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,300,000Source | 1,400,000Source | 800,000Source | 1,300,000Source | 1,200,000Source | 1,300,000Source | 4,800,000Source | 5,600,000Source | 5,500,000Source | 5,300,000Source |
| Research and Development ExpenseUSD | — | — | 32,532,000Source | 26,243,000Source | 57,832,000Source | 33,495,000Source | 31,984,000Source | 32,780,000Source | 129,619,000Source | 119,484,000Source | 103,785,000Source | 85,725,000Source |
| Selling and Marketing ExpenseUSD | — | — | 313,000Source | 11,985,000Source | — | 2,676,000Source | 198,000Source | 1,378,000Source | 4,843,000Source | 23,791,000Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Income (Loss) from Equity Method Investments | — | — | — | — | —Source | — | — | — | — | — | — | — |
Filing attachments
mgtx-ex99d1.htm · 8-K · 2026-11-12
Exhibit 99.1 MeiraGTx Reports Third Quarter 2026 Financial and Operational Results ●Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026 ●Submission of full Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bota-vec expected in the first quarter of 2027 ●12-month data readout in pivotal Pha…
Read attachment ↗mgtx-20260922xex99d1.htm · 8-K · 2026-09-23
Exhibit 99.1 MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in publ…
Read attachment ↗mgtx-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 mgtx-20260813xex99d1.htm EX-99.1 Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked ret…
Read attachment ↗mgtx-20260630xex99d1.htm · 8-K · 2026-07-07
EX-99.1 5 mgtx-20260630xex99d1.htm EX-99.1 Exhibit 99.1 MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) - MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment - Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of gra…
Read attachment ↗mgtx-20260514xex99d1.htm · 8-K · 2026-05-14
EX-99.1 2 mgtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 MeiraGTx Reports First Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 - Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia - Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of…
Read attachment ↗mgtx-20260415xex99d1.htm · 8-K · 2026-04-16
EX-99.1 4 mgtx-20260415xex99d1.htm EX-99.1 Exhibit 99.1 MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) - MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON…
Read attachment ↗